Clinical TrailsMerck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Merck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Read Post »
Clinical Trails55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... 55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... Read Post »
New Drug ApprovalHERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC HERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC Read Post »
New Drug ApprovalFDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia FDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia Read Post »
Clinical TrailsAbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... AbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... Read Post »
Clinical TrailsMerck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Merck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Read Post »
Clinical TrailsSystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... SystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... Read Post »
Clinical TrailsOrganon Highlights VTAMA Family Sleep Benefits in ADORING Trials Organon Highlights VTAMA Family Sleep Benefits in ADORING Trials Read Post »
Clinical TrailsLilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Lilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Read Post »
New Drug ApprovalFDA Approves BioMarin PALYNZIQ for Adolescents with PKU FDA Approves BioMarin PALYNZIQ for Adolescents with PKU Read Post »
Clinical TrailsBayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Bayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Read Post »
Clinical TrailsGalderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Galderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Read Post »
Clinical TrailsPalvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Palvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Read Post »
Clinical TrailsArgenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Argenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Read Post »
Clinical TrailsEli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Read Post »
New Drug ApprovalJ&J Seeks FDA Approval of IMAAVY® as First Treatment for wAIHA J&J Seeks FDA Approval of IMAAVY® as First Treatment for wAIHA Read Post »
Clinical TrailsViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data ViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data Read Post »
Clinical TrailsAxsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Axsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Read Post »
Clinical TrailsPromising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Promising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Read Post »
Drugs Safety AlertFDA Halts New Enrollment in MacroGenics’ Lorigerlimab Trial Over Safe... FDA Halts New Enrollment in MacroGenics’ Lorigerlimab Trial Over Safe... Read Post »
Clinical TrailsBristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Bristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Read Post »
New Drug ApprovalFDA Grants Full Approval to Pfizer’s BRAFTOVI Regimen FDA Grants Full Approval to Pfizer’s BRAFTOVI Regimen Read Post »
New Drug ApprovalDupixent Approved by FDA: Sanofi & Regeneron’s First Treatment fo... Dupixent Approved by FDA: Sanofi & Regeneron’s First Treatment fo... Read Post »
Clinical TrailsNovartis RWE: Pluvicto Delivers 13.5-Month PFS in ARPI-Pre-Treated mCRPC Novartis RWE: Pluvicto Delivers 13.5-Month PFS in ARPI-Pre-Treated mCRPC Read Post »
Clinical TrailsNovo Nordisk-Backed Triple Agonist UBT251 Delivers Strong Phase 2 Results i... Novo Nordisk-Backed Triple Agonist UBT251 Delivers Strong Phase 2 Results i... Read Post »
Clinical TrailsMoonLake’s SLK Shows Strong Results in Phase 2 Trial for Axial Spondy... MoonLake’s SLK Shows Strong Results in Phase 2 Trial for Axial Spondy... Read Post »
Clinical TrailsGossamer Bio’s PROSERA Trial: Narrow Miss on 6MWD, Strong in Advanced... Gossamer Bio’s PROSERA Trial: Narrow Miss on 6MWD, Strong in Advanced... Read Post »
Clinical TrailsCagriSema Delivers 23% Weight Loss in REDEFINE 4: Strong Efficacy, Just Shy... CagriSema Delivers 23% Weight Loss in REDEFINE 4: Strong Efficacy, Just Shy... Read Post »
New Drug ApprovalFDA Approves Zepbound 4-Dose KwikPen for Obesity Care FDA Approves Zepbound 4-Dose KwikPen for Obesity Care Read Post »
Clinical Trails Policy & AcquisitionsGilead Snaps Up Arcellx, Eyes Anito-cel Approval in Multiple Myeloma Gilead Snaps Up Arcellx, Eyes Anito-cel Approval in Multiple Myeloma Read Post »
Clinical TrailsFrom Week 44 to 140: New TREMFYA® Evidence Reinforces Long-Term UC Control... From Week 44 to 140: New TREMFYA® Evidence Reinforces Long-Term UC Control... Read Post »
Drugs Safety AlertNew GBS Safety Information Added to GSK’s SHINGRIX Label New GBS Safety Information Added to GSK’s SHINGRIX Label Read Post »
New Drug ApprovalFDA Approves BYSANTI™: A New Ally in Bipolar I and Schizophrenia Treatmen... FDA Approves BYSANTI™: A New Ally in Bipolar I and Schizophrenia Treatmen... Read Post »
New Drug ApprovalChugai report Anti-CD20 Monoclonal Antibody Rituxan® Approved for AIHA Chugai report Anti-CD20 Monoclonal Antibody Rituxan® Approved for AIHA Read Post »
Clinical TrailsTakeda KEPLER Trial: Promising Vedolizumab Results for Pediatric Ulcerative... Takeda KEPLER Trial: Promising Vedolizumab Results for Pediatric Ulcerative... Read Post »
New Drug ApprovalAbbVie’s VENCLEXTA Taps AZ’s Acalabrutinib for FDA’s Firs... AbbVie’s VENCLEXTA Taps AZ’s Acalabrutinib for FDA’s Firs... Read Post »
New Drug ApprovalEuropean Commission Grants Conditional Approval for ANKTIVA® in BCG-Unresp... European Commission Grants Conditional Approval for ANKTIVA® in BCG-Unresp... Read Post »
Clinical TrailsViiV Healthcare’s Cabenuva Demonstrates Superior Efficacy in LATITUDE... ViiV Healthcare’s Cabenuva Demonstrates Superior Efficacy in LATITUDE... Read Post »
Clinical TrailsMerck’s ENFLONSIA Shows Promising Safety in Second RSV Season for Hig... Merck’s ENFLONSIA Shows Promising Safety in Second RSV Season for Hig... Read Post »
Clinical TrailsPfizer Advances BRAFTOVI in Colorectal Cancer with New BREAKWATER Results Pfizer Advances BRAFTOVI in Colorectal Cancer with New BREAKWATER Results Read Post »
Clinical TrailsNovartis’ Remibrutinib Shows Promise in Chronic Inducible Urticaria Novartis’ Remibrutinib Shows Promise in Chronic Inducible Urticaria Read Post »
New Drug ApprovalFDA Approves Simplified Monthly Dosing for RYBREVANT FASPRO™ in EGFR-Muta... FDA Approves Simplified Monthly Dosing for RYBREVANT FASPRO™ in EGFR-Muta... Read Post »
Clinical TrailsViiV Healthcare Highlights Lotivibart and Cabotegravir LA Findings at CROI ... ViiV Healthcare Highlights Lotivibart and Cabotegravir LA Findings at CROI ... Read Post »
Clinical TrailsOcular Therapeutix’s AXPAXLI Achieves Superiority in Wet AMD Phase 3 ... Ocular Therapeutix’s AXPAXLI Achieves Superiority in Wet AMD Phase 3 ... Read Post »
New Drug ApprovalGSK’s Exdensur Gains EU Approval for Severe Asthma and CRSwNP GSK’s Exdensur Gains EU Approval for Severe Asthma and CRSwNP Read Post »
Clinical TrailsSanofi and Teva Report Durable Duvakitug Efficacy at 44 Weeks in UC/CD: REL... Sanofi and Teva Report Durable Duvakitug Efficacy at 44 Weeks in UC/CD: REL... Read Post »
Clinical TrailsUltragenyx Reports Long-Term Success of UX111 Gene Therapy for Sanfilippo S... Ultragenyx Reports Long-Term Success of UX111 Gene Therapy for Sanfilippo S... Read Post »
Drugs Safety AlertValneva’s IXCHIQ Gets UK Safety Restrictions for Older Adults Valneva’s IXCHIQ Gets UK Safety Restrictions for Older Adults Read Post »
Clinical TrailsRoche’s Gazyva/Gazyvaro Hits pMN Remission in Phase III MAJESTY Trial Roche’s Gazyva/Gazyvaro Hits pMN Remission in Phase III MAJESTY Trial Read Post »
